Evolus Inc (EOLS) News & EventsEOLSNews & EventsEvolus Inc

Evolus Reports Q2 Revenue of $84.1M, Beating Expectations

Reports Q2 revenue $84.1M, consensus $81.54M. "The increasing momentum of our portfolio focus has resulted in Evolus gaining significant share across injectable aesthetics during the second quarter, supported by double-digit growth for Jeuveau and accelerating adoption of Evolysse," said David Moatazedi, President and Chief Executive Officer of Evolus. "We delivered another quarter of consistent execution, highlighted by 21% revenue growth and a third consecutive quarter of positive Adjusted EBITDA, representing a $12.6 million improvement over the prior-year period. Based on our first-half results, we are raising our full-year 2026 financial outlook while continuing to invest in strategic opportunities that strengthen our long-term growth profile. At the same time, the injectable aesthetics market strengthened during the quarter, with improving consumer demand and stable treatment intervals driving mid-single digit growth in the neurotoxin market and, importantly, the hyaluronic acid category returning to positive growth following two years of declines."

Company Adjusts 2026 Gross Margin to 67.0%-67.5%

Consensus $330.45M. Raises adjusted gross profit margin for the full-year 2026 to between 67.0% and 67.5%, from 65.5% to 67.0%, reflecting an evolving revenue mix while maintaining a disciplined approach to margin optimization. Narrows non-GAAP operating expenses for the full-year 2026 to between $212 million and $216 million, from $210 million to $216 million, representing a modest 1% to 3% growth over 2025 non-GAAP operating expenses, and reflecting continued disciplined expense management while supporting strategic investments in long-term portfolio expansion. Reaffirms its 2028 long-term financial outlook reflecting total net revenue between $450 million and $500 million, representing a three-year CAGR of 15% to 19%, and Adjusted EBITDA margins of 13% to 15% for 2028.

Evolus Expands Partnership with Symatese, Gains Exclusive Rights in Canada and More

Evolus announced it has expanded its partnership with Symatese through an amendment to the companies' existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme collection of injectable hyaluronic acid gels in Canada, Australia, and New Zealand. "The addition of Canada, Australia and New Zealand is the final step that allows Evolus to offer the portfolio of Nuceiva and Estyme in every international market where we compete," said David Moatazedi, President and Chief Executive Officer of Evolus. "From the beginning, our vision has been to provide customers with a complementary portfolio of best-in-class injectable products that can address the range of aesthetic patient needs. This alignment of our portfolio ensures we can deliver a consistent Evolus experience, strengthens our competitive position, and allows us to maximize the long-term value of the commercial platform we have built."